Axalbion SA
Axalbion’s TRPM8 agonists offer new therapeutic approaches
Axalbion is a clinical-stage pharmaceutical company developing TRPM8 agonists for the treatment of chronic cough and dry eyes, two chronic, common and debilitating disorders, with limited treatment options.
Our molecules have a rapid onset of action and offer innovative topical treatment opportunities by normalizing abnormal cough and lacrimation reflexes and by decreasing sensory discomfort.
Our lead compound AX-8 is at the clinical stage of development for chronic cough.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
No news
No milestones
No Jobs
No videos and documents
No Awards
Axalbion SA
Axalbion’s TRPM8 agonists offer new therapeutic approaches
Website:
www.axalbion.com/
Headquarter:
Lausanne
Foundation Date:
January 2017
Technology:
- Biotech
Sectors:
- Drug discovery